Moreover, in clinical trials, patients with metastatic colorectal cancer receiving adoptively transferred autologous CEA-specific CAR-T experienced dose-limiting toxicity and severe transient inflammatory colitis. This evidence concerns the gene CEACAM5 and metastatic colorectal cancer.